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A series of six diﬀerent 1,8-naphthalimide conjugated dipicolylamine ligands (L1–6) have been synthesised
and characterised. The ligands possess a range of diﬀerent linker units between the napthalimide ﬂuoro-
phore and dipcolylamine chelator which allow the overall lipophilicity to be tuned. A corresponding series
of Re(I) complexes have been synthesised of the form fac-[Re(CO)3(L
1–6)]BF4. The absorption and lumine-
scence properties of the ligands and Re(I) complexes were dominated by the intramolecular charge trans-
fer character of the substituted ﬂuorophore (typically absorption ca. 425 nm and emission ca. 520 nm).
Photophysical assessments show that some of the variants are moderately bright. Radiolabelling experi-
ments using a water soluble ligand variant (L5) were successfully undertaken and optimised with fac-
[99mTc(CO)3(H2O)3]
+. Confocal ﬂuorescence microscopy showed that fac-[Re(CO)3(L
5)]+ localises in the
mitochondria of MCF-7 cells. SPECT/CT imaging experiments on naïve mice showed that fac-[99mTc
(CO)3(L
5)]+ has a relatively high stability in vivo but did not show any cardiac uptake, demonstrating rapid
clearance, predominantly via the biliary system along with a moderate amount cleared renally.
Introduction
The diﬀerent bioimaging modalities each have intrinsic
strengths and weaknesses, with no single clinically used tech-
nique providing comprehensive information. Prospective
multimodal imaging agents are designed to combine the
strengths of individual modalities, while oﬀering complemen-
tary or additional clinically useful information not provided by
a single technique.1,2 Single photon emission computed tom-
ography (SPECT) is a high sensitivity nuclear imaging tech-
nique using short half-life gamma emitting radioisotopes that
can image the whole body. In comparison, optical fluorescence
imaging can utilise agents that emit visible or near-IR photons
and can be applied to both pre-clinical in vivo and cellular
microscopy studies. However, it lacks the excellent tissue pene-
tration oﬀered by nuclear imaging modalities.
The combination of radioimaging and fluorescence
imaging presents significant opportunities in the design of
useful imaging agents.3 Combined single molecule SPECT/
fluorescence agents can provide early phase high sensitivity
imaging of in vivo biodistribution using SPECT, followed by
longitudinal optical imaging.4 Additionally, PET or SPECT
imaging can be used to identify diseased tissue non-invasively,
which can then be accurately biopsied or surgically resected
based upon the fluorescence imaging signal.5–7
The clinical use of 99mTc in SPECT imaging has been well
established for many decades. 99mTc (t1/2 = 6.01 h, γ = 142.7
keV) is a gamma emitting radioactive isotope which is used in
>80% of clinical nuclear diagnostic imaging scans, with over
40 million SPECT scans carried out per year worldwide.8 What
is less well understood is the behaviour of Tc agents at the
sub-cellular level, since the image resolution of SPECT does
not allow such determinations. Therefore intrinsically lumi-
nescent or fluorescently tagged 99mTc SPECT agents9 are
potentially helpful in correlating in vitro and in vivo imaging
properties,10 and in determining their cellular uptake, traﬃck-
ing and localisation.11 From an inorganic chemistry perspec-
tive, non-radioactive rhenium is the obvious choice for devel-
oping structurally analogous and chemically related com-
plexes.12 Such an approach can be used to validate the develop-
ment of appropriate chelates13 for 99mTc and develop experi-
mental protocols for synthesis and purification.14 Indeed,
rhenium complexes are now attracting considerable attention;
in part for their potential as cancer therapy agents15 as well as
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the existence of accessible radioisotopes appropriate for
radionuclide therapies/theranostic applications.16 Binuclear
Re(I) carbonyl complexes have shown accumulation in mito-
chondria leading to cell death.17 Indeed a bimetallic
Re(I)/99mTc(I) complex has also been described where the emis-
sive nature of the Re(I) fragment can be exploited in optical
studies.18 In the case of fluorescently tagged rhenium com-
plexes, these species can be assessed with respect to cellular
uptake using conventional confocal fluorescence microscopy
techniques.19
Whilst substituted 1,8-naphthalimides have been previously
investigated in biological assays for their therapeutic appli-
cations,20 more recent studies have shown that such species
can also be very useful fluorophores for fluorescence bio-
imaging of cells.21–23 The relative ease of functionalisation
together with advantageous absorption and emission pro-
perties in the visible region have led to a large number of
reports on their application to cell imaging. For example,
recent studies have shown that the 1,8-naphthalimide struc-
ture can dictate intracellular localisation, including eﬀective
mitochondrial targeting.24
Since mitochondria have essential roles in energy pro-
duction, cell signalling, cell-cycle control and cell death, and
mitochondrial function can be disrupted in both ischaemic
heart cells and cancer cells, they are attractive targets. Thus
the development of a SPECT/fluorescence multimodal imaging
agents for targeting mitochondria would therefore allow for
in vitro, in vivo and ex vivo examination of myocardial function
and tumour growth.25 In this context, this current work
describes the development of 1,8-naphthalimide functiona-
lised chelates suitable for labelling with 99mTc(I) for mitochon-
drial targeted multimodal imaging. During the course of these
studies, work by Turnbull et al. has shown that a series of
related 4-amino-1,8-naphthalimide fluorophores can be com-
plexed with Re(I)/99mTc(I). The overall charge of the complex
was shown to strongly influence the biological attributes of the
species.26
Synthesis and characterisation of
ligands and complexes
Scheme 1 shows the diﬀerent chelator structures that were syn-
thesised in this study. The compounds were designed to meet
the coordination chemistry requirements of M(I) (where M =
Re, Tc) with a face-capping tridentate donor set, fulfilled by a
dipicolylamine (DPA)27 chelating moiety. This is linked to the
naphthalimide fluorophore for optical imaging via diﬀerent
length spacers of variable hydro- and lipophilicity. Thus, a
series of six ligands were synthesised in three or four steps
from 4-chloro-1,8-naphthalic anhydride (Scheme 2).
Substitution at the 4-chloro position of the naphthalimide ring
was achieved in DMSO at elevated temperature using an excess
of diamine (often as the mono-Boc protected version).
Following cleavage of the Boc group (trifluoroacetic acid in di-
chloromethane), treatment of N1–6 with 2-pyridinecarboxalde-
hyde in a one-pot reductive amination procedure gave the di-
picolylamine derived target ligands, L1–6, in each case. All
experimental details and spectroscopic characterisation data
for the synthesis of intermediates and ligands are included in
the Experimental section.
Scheme 1 Design aspects of the compounds synthesised in this study
to provide a ﬂuorophore functionalised chelate to the {M(CO)3}
+ unit (M
= 99mTc, Re). Six derivatives (L1–6) were synthesised with three diﬀerent
linker units.
Scheme 2 Synthesis of the precursors and ligands. Reagents and con-
ditions: (i) N-Boc-ethylenediamine, DMSO, heat; then TFA/DCM; (ii) 1,6-
diaminohexane, DMSO, heat; (iii) 2-pyridinecarboxaldehyde, NaBH
(OAc)3, 1,2-dichloroethane; (iv) N-Boc(2,2’-(ethylenedioxy)diethylamine,
DMSO, heat; then TFA/DCM.
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All isotopes of technetium are radioactive, and so natural
rhenium is commonly used as a chemical analogue28 to allow
the synthetic and purification protocols to be optimised prior
to the use of a radionuclide. The corresponding tricarbonyl
Re(I) complexes were isolated by reacting29 the precursor com-
pounds with fac-[Re(CO)3(MeCN)3]BF4 to yield fac-[Re(CO)3(L)]
BF4 as air stable solids. Characterisation of the complexes was
achieved using a range of spectroscopic and analytical tech-
niques. The expected facial geometry with respect to the three
carbonyl ligands was confirmed using IR spectroscopy. In all
cases two CuO stretches were observed between
2040–1900 cm−1 which are attributed to the pseudo C3v sym-
metry of the complexes. In addition to this, the naphthalimide
carbonyl stretches were observed at 1700–1625 cm−1 and the
[BF4]
− counter anion at ca. 1055 cm−1. High resolution mass
spectrometry data were obtained for each complex identifying
the cationic fragment with the appropriate isotopic distri-
bution for rhenium. 1H NMR spectroscopy was able to clearly
establish the formation of the complex in each case. Firstly,
the methylene linkers of the dipicolylamine unit shift upon
coordination and become diastereotopic with an observed
coupling around 16 Hz.28 The aliphatic protons of the linker
unit are also mildly shifted in the complex versus the ligand.
The general pattern amongst the aromatic proton resonances
is retained upon formation of the complex. Principally, data
from 13C NMR studies allowed identification, in all cases, of
the rhenium-bound carbonyls (ca. 195 ppm) and the naphtha-
limide carbonyls (ca. 165 ppm).
Luminescence properties
Prior to radiolabelling and imaging studies, the electronic and
optical properties of these species were investigated (Table 1).
The UV-vis. spectra of all ligands were recorded in MeCN or
chloroform solutions. Because of the relative hydrophilicity of
the L5/L6 systems, additional data in aqueous solution was
also obtained on these ligands and their complexes. The
absorption spectra showed some common features, with
higher energy absorptions associated with the naphthalimide
and pyridyl based π–π* transitions, and a lower energy, broad
peak around 440 nm which was assigned to an intramolecular
charge transfer (ICT) transition from the amine-functionalised
naphthalimide chromophore. The position of the ICT peak
showed a slight shift that was dependent upon the amine sub-
stituent and was shown to be sensitive to the polarity of
solvent, as expected for a charge transfer transition.30 The
absorption spectra of the corresponding Re(I) complexes (for
example, Fig. 1) were comparable, with only minor shifts of
the ICT band upon formation of the cationic Re(I) complex
that are likely to be a result of the cationic charge perturbing
the ICT transition.31 Typically the molar absorption coeﬃ-
cients (Table 1) of the ICT bands in the complexes were in the
range of 7000–20 000 M−1 cm−1.
Steady state emission spectra were obtained using an
irradiation wavelength of 425 nm, corresponding to direct exci-
tation of the ICT band of the ligand. All ligands and complexes
showed an intense, featureless luminescence peak at
505–550 nm, giving Stokes’ shift >3500 cm−1, which is typical
of this class of fluorophore (for example, Fig. 2). Again, the
position of the peak was found to be moderately sensitive to
the amine substituent (related to the relative electron donating
power) and the solvent polarity. For example, measurements in
aqueous media for L5/L6 and their complexes resulted in a
bathochromic shift of the emission maxima to ca. 540 nm,
typical of positive solvatochromism (Fig. 2). Time-resolved
experiments revealed lifetimes <15 ns in all cases, confirming
the fluorescent nature of these ICT emitting species. Quantum
yields were obtained for each species in the various solvents,
and ranged 8–67%. For L5/L6 and their rhenium(I) complexes
Table 1 Solvent dependent intramolecular charge transfer absorption
and emission data for the ligands and rhenium(I) complexes
Compound
λabs (ε/M
−1 cm−1)/
nm
λem/
nma τobs/ns
b ϕ/%c
L1 434 (9310)d 518d 11.1d 15d
428 (7800)e 508e 9.8e 19e
L2 436 (10 420)d 521d 10.5d 22d
427 (8160)e 510e 8.5e 17e
L3 433 (7300)d 518d 9.7d 28d
435 (8240)e 508e 1.4, 8.8 (94%)e 28e
L4 429 (8000)d 517d 9.5d 31d
430 (18 600)e 505e 8.1e 35e
L5 448 (10 220) f 542 f 3.4, 6.0 (64%) f 39 f
429 (8910)d 521d 9.4d 12d
L6 448 (2620) f 549 f 5.4 f 8 f
429 (7920)d 520d 9.7d 30d
[Re(CO)3(L
1)]BF4 430 (8560)
d 515d 10.9d 67d
432 (7510)e 503e 9.1e 23e
[Re(CO)3(L
2)]BF4 433 (19 200)
d 519d 9.8d 30d
430 (14 300)e 504e 9.2e 37e
[Re(CO)3(L
3)]BF4 430 (16 300)
d 520d 9.8d 26d
434 (10 100)e 512e 7.7e 29e
[Re(CO)3(L
4)]BF4 431 (13 020)
d 517d 10.2d 40d
425 (18 660)e 483e 8.0e 38e
[Re(CO)3(L
5)]BF4 446 (7190)
f 540 f 6.0 f 49 f
429 (8100)d 526d 10.0d 15d
[Re(CO)3(L
6)]BF4 445 (10 700)
f 539 f 5.9 f 57 f
448 (12 240)d 516d 11.1d 17d
aMeasurements obtained in aerated solutions; λex = 405 nm.
b λex =
295 nm. cUsing aerated MeCN solution of [Ru(bipy)3](PF6)2 as a refer-
ence. d In acetonitrile. e In chloroform. f In water.
Fig. 1 UV-vis. absorption spectrum for fac-[Re(CO)3(L
5)]BF4 recorded in
water.
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these values were relatively high (around 50%) for the aqueous
solutions. Taken together this gives a typical brightness value
around 5000 M−1 cm−1. The naphthalimide conjugated
rhenium(I) complexes are thus well suited to cell imaging via
confocal fluorescence microscopy, with visible fluorescence,
good Stokes’ shifts and relatively high quantum yields giving
reasonably bright fluorophores.
Radiolabelling with technetium-99m
Having established the Re(I) coordination chemistry and the
optical properties of the complexes, radiolabelling of selected
ligand systems was attempted with the SPECT imaging
(gamma emitting) isotope technetium-99m. Radiolabelling
studies were conducted using fac-[99mTc(CO)3(H2O)3]
+, which
was obtained from the reduction of [99mTcO4]
− using the
method reported by Alberto et al.32,33 Initial attempts to radi-
olabel L1 (the ligand variant with an ethylene linker between
the naphthalimide and the dipicolylamine chelate unit) led to
the formation of a number of radioactive species indicative,
perhaps, of the decomposition of the ligand. Certainly, the
limited aqueous solubility of L1 was likely to be a hindrance to
eﬃcient radiolabelling.
Therefore, the focus of further radiochemistry experiments
was focussed upon the more hydrophilic naphthalimide L5
(the ligand variant incorporating the ethylenedioxodiamine
linker) which demonstrated good water solubility.
Preliminary experiments with water-soluble L5 indicated
much better radiolabelling yields and limited degradation
(Fig. 3),34 and therefore a range of conditions were tested to
optimise the radiolabelling reaction (Table 2). Varying quan-
tities of lyophilised L5 (15 to 300 μg), were radiolabelled with
freshly reduced fac-[99mTc(CO)3(H2O)3]
+ (10–40 MBq,
0.13–2.6 mM final precursor concentration, pH 7–8, buﬀered
with 5 mM PBS) at 70 °C. The radiolabelling yield was deter-
mined by integration of radio-HPLC traces and, at 30 min,
varied from 23% to 57%, plateauing at 55–57% for 30–150 μg
(0.26–1.32 mM) range while declining to 43% when the
amount of L5 was increased to 300 μg (2.0 mM). Increasing the
reaction time to 60 min only had an eﬀect on the lowest con-
centration (0.13 mM), with the yield increasing from 23% to
39%. Similarly, a three-fold increase of fac-[99mTc(CO)3(H2O)3]
+
(up to 124–135 MBq) did not have any observable eﬀect on the
radiolabelling yield at 0.53–1.32 mM precursor concentrations.
Thus, optimised L5 radiolabelling conditions were fixed at
0.53–1.32 mM precursor concentration, pH 7–8 (PBS), 70 °C,
30 min (Fig. 3).
Stability and mitochondrial uptake of fac-[99mTc(CO)3(L
5)]+
Lipophilicity is an important parameter in dictating the cellu-
lar localisation of organometallic complexes.35 Lipophilicity
(logD7.4) measurements were carried out on the radiolabelled
species fac-[99mTc(CO)3(L
5)]+ and showed a value of 0.67 ± 0.06.
This suggests a species with suitable solubility for biological
studies, but passive cell membrane permeability is likely to be
less favourable.36 For drug-like species, such a value can also
indicate that a renal clearance pathway will be observed.37 To
mimic in vivo conditions, formulated fac-[99mTc(CO)3(L
5)]+ was
incubated with human serum at 37 °C. HPLC analysis did not
reveal any significant instability up to 3 hours, indicating that
the radiolabelled compound had suﬃcient stability to progress
to preliminary in vivo imaging experiments.
To investigate fac-[99mTc(CO)3(L
5)]+ behaviour towards mito-
chondria, experiments were carried out using mitochondria
freshly isolated from rat heart tissue. fac-[99mTc(CO)3(L
5)]+
accumulated in the mitochondria to a higher extent (55.68 ±
6.5%) than complexes containing the cationic triphenylpho-
Fig. 2 Luminescence spectrum for fac-[Re(CO)3(L
5)]BF4 recorded in
water (λex = 425 nm).
Fig. 3 Preparation (top) and stability assessments (bottom) of radio-
labelled L5: comparative HPLC traces for fac-[Re(CO)3(L
5)]+ and fac-
[99mTc(CO)3(L
5)]+.
Table 2 Radiochemical yields for the formation of fac-
[99mTc(CO)3(L
5)]+
L5 conc. (mM) 30 min 60 min 90 min
0.2 43 47 53
0.4 51 53 55
1.0 56 57 57
2.0 42 41 43
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sphonium mitochondria targeting group that has been fre-
quently used in mitochondrial targeting.38 This uptake was
highly dependent on mitochondrial membrane potential
(MMP) as shown by a nearly complete abrogation (1.35 ±
0.14%) when the MMP was depolarised using carbonyl cyanide
m-chlorophenylhydrazine (CCCP).
Cell imaging studies with fac-[Re(CO)3(L
5)]+ and preliminary
in vivo assessment of fac-[99mTc(CO)3(L
5)]+
Cellular cytotoxicity was assessed using U87 cells in vitro by
the MTT assay, giving a CC50 value of 72.7 μM (Fig. 4), which
indicates low cytotoxicity in vitro for the compound. Whole cell
mitochondrial uptake of fac-[Re(CO)3(L
5)]+ was then studied
using confocal fluorescence microscopy in human breast
cancer cells (MCF-7) in culture. As a control, a benzyl chloride
based mitochondrial stain (MitoTracker deep red, MDR) was
used for dye co-localisation studies as its emission wavelength
(665 nm) is suﬃciently diﬀerent from fac-[Re(CO)3(L
5)]+
(540 nm) thus allowing independent detection. Confocal fluo-
rescence microscopy studies into the mitochondrial localis-
ation for fac-[Re(CO)3(L
5)]+ with MCF-7 cells gave an overlap
coeﬃcient of 0.66 (Fig. 5) suggesting a good degree of co-
localisation.
Having established the mitochondrial and cellular uptake
properties, a scoping in vivo experiment was carried out with
fac-[99mTc(CO)3(L
5)]+ in a naïve mouse using SPECT/CT
imaging (Fig. 6). Firstly, there were no signs of toxicity to the
mouse during the in vivo studies. The tracer showed rapid
clearance, predominantly via the biliary system along with a
moderate amount cleared renally. This is consistent with the
log D of fac-[99mTc(CO)3(L
5)]+, as some renal clearance was
observed and more complex active transport mechanisms can
influence hepatobiliary clearance.39 Urine analysis demon-
strated that the tracer was of a relatively high stability (85.4 ±
1.4%) and suitable for further in vivo analysis. From these
imaging studies, it was clear that cardiac uptake was not
observed for fac-[99mTc(CO)3(L
5)]+. This suggests that in its
current form the tracer will not be appropriate for assessing
cardiac function in vivo and so structural modification would
be required to ensure uptake and retention.
Fig. 4 Cell viability assay (MTT) result for fac-[Re(CO)3(L
5)]+.
Fig. 5 Confocal ﬂuorescence microscopy images of MCF-7 cells incu-
bated with fac-[Re(CO)3(L
5)]+ (top left) and MitoTracker deep red (top
right) and overlay (bottom; overlap coeﬃcient = 0.66).
Fig. 6 SPECT and CT overlaid images with the SPECT images acquired
using the radiotracer fac-[99mTc(CO)3(L
5)]+. Sagittal and coronal views
show the localisation of the tracer after 22–60 min. Red arrow: gall
bladder; yellow arrow: biliary clearance into the biliary tract and small
intestine; green arrow: bladder; blue arrow: kidney.
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Conclusions
In conclusion, this study shows the design, synthesis and
characterisation of a new class of radiotracer which is preferen-
tially taken up into the mitochondria of cells. The tracer com-
bines a naphthalimide fluorophore with a technetium(I) tricar-
bonyl unit to give a structure with excellent cellular and mito-
chondrial uptake characteristics. Cellular bioimaging shows
good image quality in the MCF-7 cell line. The preliminary
in vivo assessment of the aqueous soluble 99mTc(I) compound
shows rapid clearance, aligning with the requirements for
nuclear imaging to ensure background signal is minimised.
These results now justify further investigation of the tumour
uptake properties in vivo with appropriate tumour models and
larger animal cohorts.
In its current form, fac-[99mTc(CO)3(L
5)]+ does not demon-
strate cardiac uptake in vivo. Therefore, our further studies will
also consider structurally modified variants that can promote
and optimise this characteristic. During the course of these
studies, Luyt and co-workers reported a peptide-functionalised
naphthalimide-based fluorophore that can be used to target
CXCR4 expressing cells for potential dual mode imaging.40
This further suggests that the inherent fluorophore–chelate
design presented herein holds great promise for future biologi-
cal and bioimaging applications.
Experimental
General considerations
All reagents and solvents were commercially available and were
used without further purification if not stated otherwise. For
the measurement of 1H and 13C NMR spectra a Bruker
Fourier300 (300 MHz), Bruker AVANCE HD III equipped with a
BFFO SmartProbe™ (400 MHz) or Bruker AVANCE III HD with
BBO Prodigy CryoProbe (500 MHz) was used. The obtained
chemical shifts δ are reported in ppm and are referenced to
the residual solvent signal. Spin–spin coupling constants J are
given in Hz.
Low-resolution mass spectra were obtained by the staﬀ at
Cardiﬀ University. High-resolution mass spectra were carried
out at the EPSRC National Mass Spectrometry Facility at
Swansea University. High resolution mass spectral (HRMS)
data were obtained on a Waters MALDI-TOF mx at Cardiﬀ
University or on a Thermo Scientific LTQ Orbitrap XL by the
EPSRC UK National Mass Spectrometry Facility at Swansea
University. IR spectra were obtained from a Shimadzu
IR-Aﬃnity-1S FTIR. Reference to spectroscopic data are given
for known compounds. UV-Vis studies were performed on a
Shimadzu UV-1800 spectrophotometer as MeCN solutions (2.5
or 5 × 10−5 M). Photophysical data were obtained on a
JobinYvon–Horiba Fluorolog spectrometer fitted with a JY TBX
picosecond photodetection module as MeCN solutions.
Quantum yield measurements were obtained on aerated MeCN
solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated
MeCN as a standard (Φ = 0.016). Emission spectra were uncor-
rected and excitation spectra were instrument corrected. The
pulsed source was a nano-LED configured for 295 nm or
372 nm output operating at 1 MHz. Luminescence lifetime
profiles were obtained using the JobinYvon–Horiba FluoroHub
single photon counting module and the data fits yielded the
lifetime values using the provided DAS6 deconvolution
software.
Standard radiolabelling protocol
All work carried out with ionising radiations was carried out
within the legal requirements of the Ionising Radiations
Regulations 2017 and the Environmental Permitting
Regulations 2010. The studies followed local rules and regu-
lations to ensure safe and compliant handling of open source
radioactive materials. The labelling precursor in a glass HPLC
vial was dissolved in 50 μL of MeOH and was further diluted
with 100 μL of 10 mM PBS solution. The solution was degassed
by sonication and purged with argon for 10 min. Up to ∼400
MBq of freshly reduced fac-[99mTc(CO)3(H2O)3]
+ in a reduction
medium (∼500 μL) was added, bringing the final precursor
concentration to previously determined optimum 0.5–1.3 mM
concentration range. The reaction mixture was incubated in a
heating shaker at 70 °C mixing at 600 rpm for 30 min. After
which it was cooled down to room temperature and injected
onto semi-preparatory HPLC (ACE5 C18 5 Å 100 × 250).
Product containing fraction (RCY = 47 ± 18%, n = 3, corrected
for decay to the beginning of reaction) eluting at 12–14 min
was collected, diluted twice with deionised water and loaded
onto homemade SPE cartridge (Sep-Pak Light) containing
80–100 mg of Oasis C18 sorbent. The cartridge was washed
with 2–3 mL of deionised water and dried by a current of inert
gas. The product was eluted by 500 μL of ethanol, the solvent
was evaporated under gentle heating aided by a current of
inert gas and reformulated into PBS. For in vivo evaluation, the
formulation was filtered using a 0.22 μm filter for sterility
prior to animal administration. The decay corrected prepara-
tory yield was 21 ± 11% (n = 3) and the full process requires
less than 2 h from the start of synthesis.
Lipophilicity
Log P was measured using a standard shake-flask method.
Briefly, an aliquot of the tracer solution in ethanol (∼1 MBq)
was dried in a 1.5 mL Eppendorf tube and dissolved in 1 mL of
1 : 1 mixture of octanol/PBS. Solution was vigorously mixed in
vortex shaker for 5 min at room temperature and phases separ-
ated by centrifugation at 14.5 krpm for 2 min. 50 μL of each
phase was diluted up to 1 mL and measured using an AGC.
Serum stability
An aliquot of the tracer in ethanol (∼3 MBq) was dried, dis-
solved in 0.5 mL of human blood serum in a HPLC vial and
incubated while shaking at 600 rpm at 37 °C up to 3 hours.
Samples were taken at time 0, 30 min, 60 min, 1 h, 2 h and
3 h; the protein was precipitated by addition of double volume
of ice cold methanol and removed by centrifugation and the
supernatant analysed by radio-HPLC.
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In vivo SPECT imaging and stability
All animal procedures were approved by the University of Hull
Animal Welfare Ethical Review Body (AWERB) and carried out
in accordance with the Animals in Scientific Procedures Act 1986
and the UKCCCR Guideline 201041 by approved protocols follow-
ing institutional guidelines (Home Oﬃce Project License number
60/4549 held by Dr Cawthorne).
Female CD1 nude mice (25–30 g, Charles River, UK) were
induced with 5% and maintained under anaesthesia with 3%
isoflurane (oxygen at 1 L min−1). Temperature and respiration
were monitored throughout the scan. SPECT-CT acquisition
was carried out on a Mediso NanoSPECT/CTPLUS, equipped
with multi-pinhole pyramid collimators. Animals were injected
i.v. with ≈30 MBq (200 µL) of fac-[99mTc(CO)3(L5)]+ 30 min
prior to a 25 min SPECT scan (energy window: 126.4–154.6
keV). To show anatomical co-registration, a CT scan (240 pro-
jections, 1 s exposure, 55 kVp X-rays) was acquired following
the SPECT scan. SPECT and CT images were reconstructed
with an iterative algorithm and with exact cone beam Filtered
Back Projection, respectively (HiSPECT, Scivis GmbH,
Germany).
After imaging experiments, mice urine was collected, pro-
teins were precipitated by addition of double volume of ice
cold methanol and removed by centrifugation at 14.5 krpm for
5 min and supernatant was analysed by radio-HPLC indicating
85.4 ± 1.4% stability (n = 1, triplicate analyses).
In vitro analysis
Cell culture. MCF-7 cells were purchased from the European
Collection of Cell Cultures and grown in RPMI-1640 media.
Media was supplemented with 10% fetal calf serum (FCS).
Human glioblastoma cell line from (U87) from ATCC and it
was cultured using DMDM media with 10% (v/v) heat inacti-
vated fetal bovine serum (FBS). Media and FCS were purchased
from Gibco/Life Technologies, UK. Cells were maintained in
Nunc 75 cm2 tissue culture flasks (Fischer Scientific, UK)
inside a humidified 5% CO2 incubator at 37 °C. Both cell lines
were divided bi-weekly for maintenance of stock at a divided
ratio of 1 : 8–1 : 10 for MCF-7 cells. For confocal and flow cyto-
metry experiments cells were counted and seeding densities
(below) were used.
Toxicity. Cells were seeded in 96 well plate with 1000 cells
per well in 200 µl growth medium. The plates were incubated
overnight at 37 °C allow cells to adhere. After 18 h media was
removed from the wells and 100 μl of treated media with
various concentrations of compounds was added. The plates
were returned to the incubator. After 72 h, MTS reagent
(Promega, UK) 20 µl was added to the wells. Plates were incu-
bated for 3 h at 37 °C. Absorbance reading were taken at
490 nm using Synergy HT microplate reader (Biotek, USA). The
absorbance value of each triplicate were averaged and the
media only absorbance was subtracted. Compounds reading
were normalised to the control reading. Empty plate and com-
pound added background analysis was carried out to ensure
low levels of non-specific fluorescence.
Flow cytometry. 1 × 105 cells per well were seeded in six-well
plates and cultured for 2–3 days until 70–80% confluent. Cell
media was removed and 1 mL 0.1% FCS-containing media was
added. Carbonyl cyanide m-chlorophenylhydrazone (CCCP,
Sigma Aldrich, UK) in DMSO (50 mM, 1 μL) was added into
three wells (1 mL total volume) and 0.1% DMSO was added to
the remaining three control wells (as a control). Plates were
placed inside a CO2 incubator for 30 min, followed by the
addition of compound (500 nM, 50 µL media) to both groups.
Plates were incubated inside the CO2 incubator at 37 °C for
1 hour, subsequently, media was removed and the cells were
washed twice with ice cold PBS buﬀer. Cells were harvested
into PBS with cell scrapper and isolated by centrifugation at
200g for 5 min at 4 °C. The pellet was re-suspended in 300 μL
of PBS and the cell suspension transferred into polypropylene
FACS tubes (Falcon 2054) and analysed by a FACScan flow cyt-
ometer (BD Biosciences Europe, Erembodegem, Belgium). Dot
plot was used to gate cells and the FL-1 channel was used to
measure variation in fluorescence intensities. Mean fluo-
rescence intensities were used to quantify for comparison.
Confocal microscopy. MCF-7 cells (2.5 × 103) and H9c2 cells
(4 × 103) were seeded in Mattak confocal dishes (P35G-1.2-20-
C, 35 mm2) and cultured for 2–3 days until 70–80% confluent.
After reaching desired cell density, the growth media was
replaced with 1 mL 0.1% FCS-containing media and cells were
treated with fac-[Re(CO)3(L
5)]+ (500 nM, 50 µL) for 1 hour
inside a CO2 incubator under 5% CO2. Mitotracker deep red
(MDR, 250 nM, 20 µL) was added 1 hour prior to compound to
obtain double labelled cells for mitochondrial co-localisation
study. After 30 min, the cells were washed twice with 1 mL PBS
and media containing 15 mM HEPES was added. Unstained
control samples of cells were used to check for auto fluo-
rescence. Live cell images were obtained using ZEN software
on a Zeiss LSM 710 inverted confocal microscope, equipped
with an incubator chamber at 37 °C. Images were obtained
using a Zeiss 63× water objective.
To measure the degree of overlap between subcellular local-
isation of fac-[Re(CO)3(L
5)]+ and MDR, a colocalisation coeﬃ-
cient was calculated following standard methods. Single-label
control samples were prepared to eliminate fluorescence overlap
between two fluorescence channels; in addition to fac-[Re
(CO)3(L
5)]+ or MDR, untreated cells were assessed in order to
eliminate background fluorescence. Single-label control samples
were imaged under the same exposure settings as double-labelled
samples. Exact coordinates were determined using crosshairs at
X and Y coordinates from single-labelled controls and were iden-
tical for double-labelled samples. Once the exact coordinates
were determined, the ZEN software gave tables containing values
of co-localisation coeﬃcient and overlap coeﬃcient.
Mitochondrial uptake of [99mTc(CO)3(L
5)]+. Cardiac mito-
chondria were isolated following a modified method based on
that reported by Boehm et al.42 A male Sprague–Dawley rat was
anaesthetised with Dolethal and the heart was excised, washed
and trimmed in cold buﬀer. The trimmed heart was trans-
ferred into a centrifuge tube containing 5 ml of ice cold buﬀer
and then minced. The minced cardiac tissue suspension was
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transferred to a Teflon glass homogeniser (Scientific
Laboratory Supplies, UK) and a further 5 ml of ice cold buﬀer
A was added (total 10 ml). 1 ml trypsin was added and gently
homogenized using a tight fitting Teflon pestle (Scientific
Laboratory Supplies, UK). After 15 min of trypsin digestion,
10 ml of trypsin inhibitor was added and mixed with three
passes of the tight fitting Teflon pestle. The tissue suspension
was then centrifuged at 600g for 10 min at 4 °C. The super-
natant was transferred into another centrifuge tube and centri-
fuged again at 8000g for 10 min at 4 °C. The resultant pellet
was resuspended in 10 ml of isolation buﬀer B and again cen-
trifuged at 8000g for 10 min at 4 °C. The mitochondrial pellet
was then resuspended in 100 µl of respiratory buﬀer contain-
ing 10 mM succinate. The total protein content of the isolated
mitochondria was measured using Bio-Rad protein assay. 10 µl
of the isolated mitochondria suspension was added into
390 µl of water (40 times dilution). A standard solution was
made with BSA to calibrate the protein amount. 60 µl of the
mitochondria suspension was added to 3 ml of Bio-Rad solu-
tion and 60 µl from each of the BSA stock solution dilutions
were also taken and added to 3 ml of Bio-Rad solution.
Mitochondrial protein concentration was shown to be
1.23 µg µl−1, as it was 40 times diluted, the original concen-
tration was 49.46 µg µl−1. Hence, the total mitochondrial
protein amount was 4946 µg in 100 µl. 150 µg protein was ali-
quoted into each Eppendorf. 100 µl of respiratory buﬀer con-
taining 10 mM succinate added to give the control (n = 3 for
each tracer). 10 µM CCCP was added into 100 µl of respiratory
buﬀer containing 10 mM succinate and was then added in
remaining Eppendorf tubes. All the Eppendorf tubes were
transferred into the CO2 incubator containing 5% CO2 at 37 °C
for 15 min and after that 0.5 MBq of tracer was added to the
control and CCCP treated mitochondria. All of the Eppendorf
tubes were transferred back into the CO2 incubator for 30 min
and after that the assay was terminated by centrifugation at
8000g for 5 min at 4 °C. The supernatant was collected and the
mitochondrial pellet was washed three times with ice cold res-
piratory buﬀer containing 10 mM succinate. After the final
wash, the mitochondrial pellet was resuspended into 1 ml of
PBS. The amount of radioactivity was measured using the
gamma counter (PerkinElmer Wallac wizard 3″). Percent
accumulation was quantified by using the ratio of activity in
pellet to that in the pellet plus supernatant. The experiment
was carried out three times using internal triplicates. The data
is presented as an average of each internal triplicate with the
standard deviation among triplicates.
Ligands and precursors
Synthesis of compound C1 .43 4-Chloro-1,8-naphthalic anhy-
dride (2 g, 8.6 mmol) was dissolved in ethanol (60 mL) and
ethanolamine (0.79 mL, 12.9 mmol) was added. The solution
was then heated at reflux for 12 h under a nitrogen atmo-
sphere. Upon cooling to 0 °C precipitation occurred, and fil-
tration yielded C1 as a yellow solid (2.01 g, 85%). 1H NMR
(400 MHz, CDCl3): δH 8.70 (d, J = 6.8 Hz, 1H), 8.64 (d, J = 8.4
Hz, 1H), 8.54 (d, J = 7.6 Hz, 1H), 7.88 (m, 2H), 4.48 (t, J = 4.8
Hz, 2H), 4.01 (t, J = 4.8 Hz, 2H) ppm. LRMS ES+ found m/z =
275.03 [M+].
Synthesis of compound C2 .44 Prepared as for C1 except
using 2-methoxyethylamine (0.90 g, 12.9 mmol), yielding C2 as
a yellow solid (1.96 g, 79%). 1H NMR (400 MHz, CDCl3): δH
8.68 (d, J = 7.0 Hz, 1H), 8.61 (d, J = 8.1 Hz, 1H), 8.52 (d, J = 8.2
Hz, 1H), 7.91–7.80 (m, 2H), 4.44 (t, J = 5.7 Hz, 2H), 3.73 (t, J =
5.7 Hz, 2H), 3.38 (s, 3H) ppm. LRMS ES+ found m/z = 289.05
[M+].
Synthesis of N1. C1 (0.3 g, 1.01 mmol) was dissolved in
DMSO (4 mL) and N-Boc-ethylenediamine was added (0.47 g,
2.93 mmol) and the solution heated at reflux for 16 hours
under a nitrogen atmosphere. The solution was flooded with
30 mL of water and neutralised with 0.1 M HCl. The product
was then extracted with dichloromethane (3 × 15 mL) and
washed with water (3 × 10 mL) and brine (3 × 10 mL). The
solvent was then reduced to a minimum and precipitation
induced by the dropwise addition of petroleum ether.
Filtration of the precipitate followed by washing with diethyl
ether (5 mL) yielded the Boc-protected intermediate product as
a bright orange solid (0.27 g, 65%). 1H NMR (300 MHz,
CDCl3): δH 8.55 (d, J = 7.3 Hz, 1H), 8.42 (d, J = 8.5 Hz, 1H), 8.27
(d, J = 8.3 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.19 (s, 1H), 6.55 (d,
J = 8.3 Hz, 1H), 4.45 (t, J = 4.3 Hz, 2H), 3.97 (s, 2H), 3.65 (dd,
J = 10.2, 5.3 Hz, 2H), 3.49–3.38 (m, 2H), 1.42 (s, 9H) ppm. 13C
{1H} NMR (101 MHz, CDCl3): δC 163.89, 163.10, 150.08, 134.03,
130.78, 129.32, 128.73, 124.48, 121.99, 120.37, 108.76, 103.95,
57.96, 41.47, 40.36, 37.31 ppm. LRMS ES+ found m/z = 400.19
[M + H]+. Deprotection of the intermediate product was
achieved by stirring the solution of the intermediate in 50%
TFA in DCM for 24 hours under a nitrogen atmosphere. The
solvents were then removed under vacuum, and the residue
dissolved in methanol and the solvent removed again. This
was repeated in triplicate to yield the final product as an oily
yellow solid (0.178 g, 60%). 1H NMR (300 MHz, d6-DMSO): δH
8.63 (d, J = 8.3 Hz, 2H), 8.42 (d, J = 7.2 Hz, 2H), 8.26 (d, J = 8.4
Hz, 2H), 7.78 (s, 2H), 7.69 (t, J = 7.8 Hz, 2H), 6.84 (d, J = 8.5 Hz,
2H), 4.84 (s, J = 46.7 Hz, 2H), 4.11 (t, J = 6.3 Hz, 4H), 3.73–3.51
(m, 8H), 3.39 (s, 2H), 3.17 (s, 4H) ppm. 13C{1H} NMR
(101 MHz, d6-DMSO): δC 163.89, 163.10, 150.08, 134.03,
130.78, 129.32, 128.73, 124.48, 121.99, 120.37, 108.76, 103.95,
57.96, 41.47, 40.36, 37.31 ppm. LRMS ES+ found m/z = 332.12
[M + Na]+. HRMS expected m/z = 322.1162 for [M + Na]+ found
m/z = 322.1163.
Synthesis of N2. Prepared as for N1 but using C2 (0.3 g,
1.0 mmol), yielding the intermediate product as a bright
orange solid (0.157 g, 38%). 1H NMR (400 MHz, CDCl3): δH
8.51 (d, J = 7.3 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.4
Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.02 (s, 1H), 6.50 (d, J = 8.3 Hz,
1H), 5.03 (s, 1H), 4.36 (t, J = 5.6 Hz, 2H), 3.65 (t, J = 5.7 Hz,
2H), 3.58 (s, 2H), 3.39 (s, 2H), 3.32 (s, 3H), 1.41 (s, 8H) ppm.
13C{1H} NMR (101 MHz, CDCl3): δC 164.33, 158.65, 150.24,
134.77, 131.32, 129.94, 127.14, 124.71, 122.77, 120.39, 103.30,
80.85, 77.24, 69.84, 58.80, 46.87, 39.50, 38.96, 28.37 ppm.
LRMS found m/z = 414.20 [M + H]+. Deprotection yielded the
final product as an orange oil (0.103 g, 87%). 1H NMR
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(400 MHz, CD3OD): δH 8.41 (d, J = 7.6 Hz, 2H), 8.28 (d, J = 8.8
Hz, 1H), 7.65–7.49 (m, 2H), 6.78 (d, J = 8.7 Hz, 1H), 4.24 (t, J =
6.0 Hz, 2H), 3.69 (t, J = 6.1 Hz, 2H), 3.59 (t, J = 6.0 Hz, 2H), 3.27
(m, 2H), 3.25 (s, 3H) ppm. LRMS found m/z = 336.13 [M + Na]+.
HRMS expected m/z = 336.1319 for [M + Na]+, found m/z =
336.1320.
Synthesis of N3. C1 (0.75 g, 2.73 mmol) was dissolved in
DMSO (4 mL) and 1,6 diaminohexane (0.4 mL, 4.1 mmol) was
added and the solution heated at reflux for 16 hours. The solu-
tion was flooded with 30 mL of water and neutralised with 0.1
M HCl. The product was then extracted with dichloromethane
(3 × 15 mL) and washed with water (3 × 10 mL) and brine (3 ×
10 mL). The solvent was then reduced to a minimum and pre-
cipitation induced by the dropwise addition of petroleum
ether. Filtration of the precipitate followed by washing with
diethyl ether (5 mL) yielded the product as an orange solid
(0.422 g, 44%). 1H NMR (300 MHz, CDCl3): δH 8.58 (d, J = 7.4
Hz, 1H), 8.46 (d, J = 7.6 Hz, 1H), 8.10 (d, J = 8.1 Hz, 1H),
7.69–7.57 (m, 1H), 6.75–6.66 (m, 1H), 5.36 (s, 1H), 4.51–4.40
(m, 2H), 4.03–3.92 (m, 2H), 3.50–3.34 (m, 2H), 2.78–2.67 (m,
2H), 1.95–1.75 (m, 2H), 1.65–1.41 (m, 6H) ppm. 13C{1H} NMR
(126 MHz, CDCl3): δC 165.58, 165.01, 150.88, 135.09, 131.38,
130.03, 127.61, 124.36, 122.09, 120.31, 108.23, 104.03, 60.41,
43.27, 42.02, 41.22, 32.52, 28.28, 26.80, 26.41. LRMS found m/z
= 356.20 [M + H]+, HRMS expected m/z = 356.1896 found m/z =
356.1965.
Synthesis of N4. Prepared as for N3 but using C2 (0.75 g,
1.38 mmol) yielding the product as an orange solid (0.420 g,
42%). 1H NMR (400 MHz, CDCl3): δH 8.59 (d, J = 7.4 Hz, 1H),
8.47 (d, J = 8.3 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 7.7
Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 5.32 (s, 1H), 4.45 (t, J = 5.8 Hz,
2H), 3.75 (t, J = 5.8 Hz, 2H), 3.57–3.30 (m, 5H), 2.74 (t, J = 6.6
Hz, 2H), 1.91–1.75 (m, 2H), 1.61–1.39 (m, 6H) ppm. 13C{1H}
NMR (126 MHz, CDCl3): δC 165.04, 164.97, 164.41, 150.14,
149.91, 134.82, 134.74, 131.30, 129.94, 129.87, 126.81, 126.50,
124.56, 124.49, 122.62, 122.55, 120.21, 120.16, 109.40, 109.14,
104.15, 104.09, 69.71, 58.66, 43.33, 41.19, 38.87, 28.62, 28.47,
26.90, 26.81, 26.40. LRMS found m/z = 370.21 [M + H]+. HRMS
expected m/z = 370.2127 for [M + H]+, found m/z = 370.2125.
Synthesis of N5. C1 (0.75 g, 2.72 mmol) was dissolved in
DMSO (5 mL) and N-Boc(2,2′-(ethylenedioxy)diethylamine
(1.4 g, 5.64 mmol) was added and the solution heated at reflux
for 16 hours under a nitrogen atmosphere. Upon being
allowed to cool the solution was flooded with 30 mL of water
and neutralised with 0.1 M HCl. The product was then
extracted with dichloromethane (3 × 15 mL) and washed with
water (3 × 10 mL) and brine (3 × 10 mL). The crude intermedi-
ate product was then purified further though the use of silica
gel column chromatography using 3 : 2 acetone hexane with
4% triethylamine as the eluent. The solvents were then
removed under vacuum yielding the intermediate product as a
red oil (0.40 g, 30%). 1H NMR (300 MHz, CDCl3): δH 8.37 (d, J =
6.8 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H),
7.46 (t, J = 7.5 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.03 (s, 1H),
5.00 (s, 1H), 4.36 (t, J = 4.8 Hz, 2H), 3.92 (t, J = 4.5 Hz, 2H),
3.82 (t, J = 5.1 Hz 2H), 3.64 (m, 4H), 3.57–3.45 (m, 4H), 3.28 (d,
J = 4.8 Hz, 2H), 1.34 (s, 9H) ppm. LRMS found m/z = 389.18 [M
+ H]+. Deprotection of the intermediate product was achieved
by stirring in 50% TFA in DCM (10 mL) for 24 hours under a
nitrogen atmosphere. The solvents were then removed under
vacuum, and the residue dissolved in methanol and the
solvent removed again. This was repeated in triplicate to yield
N5 as a red oil (0.29 g, 91%). 1H NMR (300 MHz, CD3OD): δH
8.31–8.19 (m, 2H), 8.09 (m, 1H), 7.43 (m, 1H), 6.61 (m, 1H),
4.23 (m, 2H), 3.80 (t, J = 5.1 Hz, 2H), 3.72–3.64 (m, 6H),
3.59–3.51 (m, 2H), 3.30–3.25 (m, 2H), 3.11–3.01 (m, 2H) ppm.
13C{1H} NMR (75 MHz, CD3OD): δC 164.78, 150.78, 149.04,
134.14, 133.04, 130.55, 128.31, 128.01, 127.62, 123.86, 108.00,
103.65, 70.03, 68.62, 66.54, 59.03, 42.69, 39.22 ppm. LRMS
found m/z = 388.18 [M + H]+. HRMS expected m/z = 388.1872
for [M + H]+, found m/z = 388.1857.
Synthesis of N6. Prepared as for N5 but using C2 (0.75 g,
2.59 mmol), first yielding the intermediate product as a red oil
(0.46 g, 35%). 1H NMR (400 MHz, MeOD) δ 8.35 (d, J = 7.8 Hz,
1H), 8.19 (d, J = 8.6 Hz, 1H), 7.50 (t, J = 7.9 Hz, 1H), 6.70 (d, J =
8.6 Hz, 1H), 4.23 (t, J = 6.1 Hz, 1H), 3.75 (t, J = 5.5 Hz, 1H),
3.67–3.62 (m, 1H), 3.62–3.55 (m, 8H), 3.27 (s, 1H), 2.96 (t, J =
5.1 Hz, 1H), 1.36 (s, 9H) ppm. Deprotection yielded the N5 as a
red oil (0.32 g, 88%). 1H NMR (400 MHz, CD3OD): δH 8.35 (d, J
= 7.8 Hz, 2H), 8.19 (d, J = 8.6 Hz, 1H), 7.50 (app. t, J = 7.9 Hz,
1H), 6.70 (d, J = 8.6 Hz, 1H), 4.23 (t, J = 6.1 Hz, 2H), 3.75 (t, J =
5.5 Hz, 2H), 3.67–3.62 (m, 2H), 3.62–3.55 (m, 8H), 3.27 (s, 3H),
2.96 (m, J = 5.1 Hz, 2H) ppm. 13C{1H} NMR (400 MHz,
CD3OD): δC 116.2, 165.6, 152.4, 135.7, 132.2, 131.0, 139.2,
125.5, 123.2, 121.7, 109.5, 105.2, 71.6, 71.4, 70.7, 70.1, 67.9,
58.9, 44.2, 40.5, 39.7 ppm. LRMS found m/z = 402.20 [M + H]+.
HRMS expected m/z = 402.2023 for [M + H]+, found m/z =
402.2017.
Synthesis of L1. N1 (0.11 g, 0.37 mmol) was dissolved in 1,2-
dichloroethane and 2-pyridinecarboxaldehyde (0.07 mL,
0.74 mmol) was added and the solution stirred for 2 hours
under a nitrogen atmosphere. Sodium trisacetoxyborohydride
(0.24 g, 1.11 mmol) was then added and the solution stirred at
room temperature for 18 hours. The solution was then neutral-
ised with saturated NaHCO3 and the product extracted into
chloroform, washed with water (3 × 20 mL) and brine (3 ×
20 mL). The organic layer was collected then dried over MgSO4
and filtered, and the solvent removed to yield the product as
an orange oil (0.13 g, 73%). 1H NMR (400 MHz, CDCl3):
δH 8.80 (d, J = 8.9 Hz, 1H), 8.57 (d, J = 7.3 Hz, 1H), 8.52–8.49
(m, 2H), 8.35 (d, J = 8.6 Hz, 1H), 7.98 (s, 1H), 7.68–7.60
(m, 1H), 7.55–7.47 (m, 2H), 7.31 (d, J = 7.6 Hz, 2H), 7.12–7.07
(m, 2H), 6.48 (d, J = 8.1 Hz, 1H), 4.70 (s, 1H), 4.43–4.38 (m,
2H), 3.95 (s, 4H), 3.93–3.89 (m, 2H), 3.36–3.31 (m, 2H),
3.01–2.96 (m, 2H) ppm. 13C{1H} NMR (151 MHz, CDCl3):
δC 164.76, 164.11, 160.85, 150.53, 140.25, 134.54, 131.29,
129.82, 127.09, 125.21, 125.00, 124.53, 122.60, 122.29, 120.43,
104.65, 70.46, 70.15, 69.79, 68.32, 67.72, 67.40, 58.72, 38.90,
3.67 ppm. LRMS found m/z = 482.22 [M + H]+. HRMS expected
m/z = 482.2192 for [M + H]+, found m/z = 482.2202. UV-vis.
(MeCN) λmax (ε/dm
3 mol−1 cm−1): 434 (9300), 280 (19 600), 262
(20 400) nm.
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Synthesis of L2. Prepared as for L1, but using N2 (0.10 g,
0.32 mmol), 2-pyridine carboxaldehyde (0.06 mL, 0.64 mmol),
and sodium trisacetoxyborohydride (0.203 g, 0.13 mmol).
Recrystallization from chloroform yielded the product as a
yellow crystalline solid (0.08 g, 51%). 1H NMR (400 MHz,
CDCl3): δH 8.83 (d, J = 8.2 Hz, 1H), 8.64 (d, J = 7.7 Hz, 1H),
8.59–8.56 (m, 2H), 8.42 (d, J = 8.6 Hz, 1H), 7.91 (s, 1H),
7.73–7.67 (m, 2H), 7.60–7.52 (m, 2H), 7.40–7.36 (m, 2H),
7.18–7.13 (m, 2H), 6.55 (d, J = 8.7 Hz, 1H), 4.44 (t, J = 6.0 Hz,
2H), 4.22 (t, J = 5.9 Hz, 2H), 4.01 (s, 4H), 3.73 (t, J = 6.3 Hz,
2H), 3.40 (s, 3H), 3.05 (t, J = 5.2 Hz, 2H) ppm. 13C{1H} NMR
(101 MHz, CD3OD): δC 153.26, 150.32, 147.84, 134.27, 131.02,
129.74, 128.47, 127.97, 124.60, 122.14, 120.86, 118.93, 109.67,
103.90, 69.27, 57.54, 48.94, 40.24, 39.01, 38.77, 38.45, 37.74,
36.45, 22.65, 13.02, 10.02 ppm. LRMS found m/z = 512.23 for
[M + O + H]+. HRMS expected m/z = 512.2281 for [M + O + H]+,
found m/z = 512.2292. UV-vis. (MeCN) λmax (ε/dm
3 mol−1
cm−1): 436 (10 420), 280 (19 800), 262 (20 500) nm.
Synthesis of L3. Prepared as for L1 but using N3 (0.21 g,
0.565 mmol), 2-pyridine carboxaldehyde (0.13 mL, 1.12 mmol)
and sodium trisacetoxyborohydride (0.36 g, 1.68 mmol).
Product was isolated as an orange oil (0.386 g, 95%). 1H NMR
(400 MHz, CDCl3): δH 8.48 (d, J = 4.7 Hz, 1H), 8.28 (d, J = 7.2
Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.59
(t, J = 7.6 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz,
1H), 7.11–7.06 (m, 1H), 6.42 (d, J = 8.5 Hz, 1H), 5.91 (s, 1H),
4.36 (t, J = 4.1 Hz, 1H), 3.96 (t, J = 4.6 Hz, 1H), 3.76 (s, 2H),
3.23 (t, J = 5.6 Hz, 1H), 2.48 (t, J = 7.1 Hz, 1H), 1.70–1.64 (m,
1H), 1.53–1.48 (m, 1H), 1.37–1.25 (m, 2H) ppm. 13C{1H} NMR
(101 MHz, CDCl3): δC 164.25, 163.88, 158.88, 149.05, 147.87,
147.50, 135.65, 135.43, 133.59, 130.08, 128.52, 125.53, 123.30,
121.96, 121.26, 121.22, 120.95, 119.47, 118.98, 107.92, 103.03,
63.29, 60.72, 59.38, 53.17, 42.49, 41.50, 27.55, 25.90, 25.87,
25.66 ppm. LRMS found m\z = 554.28 for [M + O + H]+. HRMS
expected m/z = 554.2753 for [M + O + H]+, found m/z =
554.2762. UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1): 433 (7300),
279 (18 200, sh), 263 (20 400) nm.
Synthesis of L4. Prepared as for L1 but using N4 (0.20 g,
0.51 mmol), 2-pyridine carboxaldehyde (0.1 mL, 1.08 mmol)
and sodium trisacetoxyborohydride (0.34 g, 1.62 mmol).
Product isolated as an orange oil (0.194 g, 69%).1H NMR
(400 MHz, CDCl3) δ 8.56–8.49 (m, 3H), 8.43 (d, J = 7.7 Hz, 1H),
8.07 (d, J = 8.6 Hz, 1H), 7.63 (t, J = 7.7 Hz, 2H), 7.59–7.49 (m,
3H), 7.16–7.09 (app. t, J = 6.4 Hz, 2H), 6.66 (d, J = 8.3 Hz, 1H),
5.37 (s, 1H), 4.42 (t, J = 5.8 Hz, 2H), 3.81 (s, 4H), 3.42–3.32 (m,
5H), 2.56 (t, J = 7.1 Hz, 2H), 1.96–1.67 (m, 4H), 1.66–1.52 (m,
2H), 1.52–1.29 (m, 2H). 13C{1H} NMR (75 MHz, CDCl3): δC
164.83, 164.20, 159.79, 149.76, 148.91, 136.50, 134.58, 131.16,
129.76, 126.28, 124.46, 122.98, 122.71, 122.02, 120.11, 109.54,
104.13, 77.53, 77.10, 76.68, 69.85, 60.40, 58.76, 54.21, 43.54,
38.91, 28.68, 26.92, 26.76 ppm. LRMS found m/z = 552.29 for
[M + H]+. HRMS expected m/z = 552.2955 for [M + H]+, found
m/z = 552.2969. UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1): 429
(8000), 282 (14 200, sh), 263 (17 500) nm.
Synthesis of L5. N5 (0.075 g, 0.19 mmol) was dissolved in 5%
triethylamine in 1,2-dichloroethane and (20 mL) and 2-pyridi-
necarboxaldehyde (0.07 mL, 0.74 mmol) was added and the
solution stirred for 2 hours under a nitrogen atmosphere.
Sodium trisacetoxyborohydride (0.24 g, 1.11 mmol) was then
added and the solution stirred at room temperature for
18 hours. The solution was then neutralised with saturated
NaHCO3 and the product extracted into chloroform, washed
with water (3 × 20 mL) and brine (3 × 20 mL). The organic
layer was then dried over MgSO4 and filtered, and the solvent
removed yielding L5 as an orange oil (0.13 g, 73%). 1H NMR
(400 MHz, CDCl3): δH 8.80 (d, J = 8.9 Hz, 1H), 8.57 (d, J = 7.3
Hz, 1H), 8.52–8.49 (m, 2H), 8.35 (d, J = 8.6 Hz, 1H), 7.98 (s,
1H), 7.68–7.60 (m, 1H), 7.55–7.47 (m, 2H), 7.31 (d, J = 7.6 Hz,
2H), 7.12–7.07 (m, 2H), 6.48 (d, J = 8.1 Hz, 1H), 4.70 (s, 1H),
4.43–4.38 (m, 2H), 3.95 (s, 4H), 3.93–3.89 (m, 2H), 3.36–3.31
(m, 2H), 3.01–2.96 (m, 2H) ppm. 13C{1H} NMR (75 MHz,
CDCl3): δC 165.52, 165.05, 159.26, 150.55, 148.88, 136.61,
134.76, 131.23, 129.77, 127.74, 124.27, 123.24, 122.13, 120.49,
109.09, 103.98, 77.52, 77.09, 76.67, 70.29, 69.25, 68.64, 61.91,
60.60, 53.83, 43.35, 42.60 ppm. LRMS found m/z = 570.27 for
[M + H]+. HRMS expected m/z = 570.2711 for [M + H]+, found
m/z = 570.2708. UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1): 429
(8190), 279 (19 200, sh), 260 (21 000) nm.
Synthesis of L6. Prepared as for L5 but using N6 (0.06 g,
0.15 mmol), 2-pyridine carboxaldehyde (0.03 g, 0.3 mmol) and
sodium trisacetoxyborohydride (0.1 g, 0.45 mmol) and triethyl-
amine (2 mL). L2 was isolated as a red oil (0.063 g, 72%). 1H
NMR (500 MHz, CDCl3): δH 8.47 (d, J = 7.3 Hz, 1H), 8.42 (d, J =
4.3 Hz, 2H), 8.38 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 7.9 Hz, 1H),
7.53 (t, J = 7.1 Hz, 2H), 7.45–7.38 (m, 3H), 7.06–7.02 (m, 2H),
6.60 (d, J = 8.5 Hz, 1H), 6.24 (s, 1H), 4.35 (t, J = 6.0 Hz, 2H),
3.87 (s, 4H), 3.79 (t, J = 4.7 Hz, 2H), 3.66 (t, J = 6.0 Hz, 2H), 3.61
(d, J = 4.8 Hz, 4H), 3.55–3.52 (m, 2H), 3.48 (d, J = 4.8 Hz, 2H)
ppm. 13C{1H} NMR (126 MHz, CDCl3): δC 165.02, 164.38, 159.72,
150.04, 149.12, 136.60, 134.74, 131.39, 130.10, 127.08, 124.66,
123.08, 122.95, 122.47, 122.15, 120.74, 110.21, 104.34, 70.48,
70.35, 69.95, 69.67, 68.71, 60.87, 58.92, 53.66, 43.28, 39.08. LRMS
found m/z = 584.28 [M + H]+. HRMS expected m/z = 584.2867 for
[M + H]+, found m/z = 584.2873. UV-vis. (MeCN) λmax
(ε/dm3 mol−1 cm−1): 429 (7920), 281 (19 600), 263 (20 600) nm.
Synthesis of fac-[Re(CO)3(L
1)]BF4. Compound L
1 (50 mg,
0.10 mmol) was dissolved in chloroform and fac-[Re
(CO)3(MeCN)3]BF4 (54 mg, 0.11 mmol) was added and the
solution stirred at reflux under a nitrogen atmosphere for 18 h.
Upon being allowed to cool, the solvent was reduced to a
minimum and the product precipitated upon the dropwise
addition of hexane. The product was then filtered to yield fac-
[Re(CO)3(L
1)]BF4 as an orange solid (21.5 mg, 35%).
1H NMR
(300 MHz, CD3CN): δH 8.78 (d, J = 5.3 Hz, 2H), 8.54 (d, J = 7.5
Hz, 1H), 8.44 (dd, J = 8.3, 5.4 Hz, 2H), 7.89 (t, J = 7.7 Hz, 2H),
7.77–7.69 (m, 1H), 7.49–7.41 (m, 2H), 7.35–7.27 (m, 2fH), 6.95
(d, J = 8.5 Hz, 1H), 6.40 (s, 1H), 5.01–4.81 (m, 4H), 4.22 (dd, J =
12.3, 6.4 Hz, 2H), 4.03–3.92 (m, 2H), 3.74 (t, J = 6.2 Hz, 2H)
ppm. 13C{1H} NMR (151 MHz, d6-DMSO): δC 196.90, 195.60,
164.33, 163.59, 160.98, 152.34, 152.29, 150.52, 141.21, 141.20,
141.15, 134.51, 131.30, 129.79, 129.02, 126.29, 125.18, 123.85,
122.64, 120.89, 109.47, 104.79, 67.77, 67.68, 67.42, 58.45,
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58.41, 41.93. LRMS found m/z = 752.15 for [M]+. HRMS
expected m/z = 752.1506 for [M]+, found m/z = 752.1515. FT-IR
(solid, selected cm−1): 2027 (CuO), 1904 (CuO), 1684 (CvO),
1638 (CvO), 1057 (BF4
−). UV-vis. (MeCN) λmax (ε/dm
3 mol−1
cm−1): 430 (8560), 281 (18 900, sh), (21 000) nm.
Synthesis of fac-[Re(CO)3(L
2)]BF4. Prepared as for fac-[Re
(CO)3(L
1)]BF4 but using compound L
2 (58 mg, 1.0 mmol). 1H
NMR (400 MHz, CDCl3): δH 8.68 (d, J = 8.0 Hz, 1H), 8.64 (d, J =
5.3 Hz, 2H), 8.59 (d, J = 7.3 Hz, 1H), 8.48 (d, J = 8.2 Hz, 1H),
7.81–7.66 (m, 5H), 7.22–7.17 (m, 2H), 6.73 (d, J = 8.5 Hz, 1H),
5.80 (d, J = 16.0 Hz, 2H), 4.52 (d, J = 16.0 Hz, 2H), 4.41 (t, J =
5.8 Hz, 2H), 4.28–4.15 (m, 4H), 3.71 (t, J = 6.7 Hz, 2H), 3.37 (s,
3H) ppm. 13C{1H} NMR (151 MHz, CDCl3): δC 195.74, 195.73,
164.76, 164.11, 160.85, 150.59, 150.53, 140.25, 134.54, 131.29,
129.82, 127.09, 125.21, 125.00, 124.53, 122.60, 122.29, 120.43,
70.46, 70.46, 70.15, 69.79, 68.32, 67.72, 67.40, 58.72, 43.70,
38.90 ppm. LRMS found m/z = 766.17 for [M]+. HRMS expected
m/z = 766.1657 for [M+], found m/z 766.1671. FT-IR (solid,
selected cm−1): 2029 (CuO), 1910 (CuO), 1684 (CvO), 1638
(CvO), 1055 (BF4
−). UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1):
433 (9800), 280 (18 400, sh), 261 (22 500) nm.
Synthesis of fac-[Re(CO)3(L
3)]BF4. Prepared as for fac-[Re
(CO)3(L
1)]BF4 but using compound L
3 (58 mg, 1.0 mmol). 1H
NMR (400 MHz, CDCl3): δH 8.68 (d, J = 8.0 Hz, 1H), 8.64 (d, J =
5.3 Hz, 2H), 8.59 (d, J = 7.3 Hz, 1H), 8.48 (d, J = 8.2 Hz, 1H),
7.81–7.66 (m, 5H), 7.22–7.17 (m, 2H), 6.73 (d, J = 8.5 Hz, 1H),
5.80 (d, J = 16.0 Hz, 2H), 4.52 (d, J = 16.0 Hz, 2H), 4.41 (t, J =
5.8 Hz, 2H), 4.28–4.15 (m, 4H), 3.71 (t, J = 6.7 Hz, 2H), 3.37 (s,
3H) ppm. 13C{1H} NMR (151 MHz, CD3OD): δC 197.13, 196.19,
166.18, 165.72, 161.91, 161.34, 153.23, 151.64, 141.75, 135.67,
132.45, 131.10, 129.28, 127.20, 127.02, 126.08, 124.81, 124.73,
110.94, 105.56, 70.70, 68.94, 68.91, 58.94, 49.85, 40.47,
39.88 ppm. LRMS found m/z = 808.21 for [M]+. HRMS expected
m/z = 808.2137 for [M]+, found m/z = 808.2140. FT-IR (solid,
selected cm−1): 2031 (CuO), 1944 (CuO), 1638 (CvO), 1072
(BF4
−). UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1): 434 (10 100),
279 (18 200), 256 (22 400) nm.
Synthesis of fac-[Re(CO)3(L
4)]BF4. Prepared as for fac-[Re
(CO)3(L
1)]BF4 but using compound L
4 (62 mg, 1.0 mmol). 1H
NMR (400 MHz, CDCl3): δH 8.66–8.54 (m, 3H), 8.52 (d, J = 7.2
Hz, 1H), 8.41 (d, J = 8.3 Hz, 1H), 7.71 (app. t, J = 7.9 Hz, 2H),
7.63 (app. t, J = 10.7 Hz, 3H), 7.15–7.10 (m, 3H), 5.73 (d, J =
16.0 Hz, 2H), 4.45 (d, J = 16.0 Hz, 2H), 4.34 (t, J = 6.3 Hz, 2H),
4.21–4.08 (m, 4H), 3.64 (t, J = 6.4 Hz, 2H), 3.31 (s, 3H), 1.14 (t, J
= 7.1 Hz, 4H) ppm. 13C{1H} NMR (151 MHz, CD3OD): δC
195.52, 195.30, 164.77, 164.25, 160.51, 159.92, 151.82, 150.21,
140.52, 140.34, 134.40, 130.92, 128.80, 127.73, 125.62, 125.43,
124.61, 123.40, 123.32, 109.53, 104.15, 69.29, 67.53, 67.50,
57.54, 48.47, 48.20, 48.10, 47.17, 46.56, 39.06, 38.48 ppm.
LRMS found m/z = 822.23 for [M]+. HRMS expected m/z =
822.2301 for [M]+, found m/z = 822.2290 for [M]+. FT-IR (solid,
selected cm−1): 2029 (CuO), 1907 (CuO), 1681 (CvO), 1639
(CvO), 1055 (BF4
−). UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1):
431 (13 020), 276 (24 400, sh), 260 (26 100) nm.
Synthesis of fac-[Re(CO)3(L
5)]BF4. Prepared as for fac-[Re
(CO)3(L
1)]BF4 but using compound L
5 (62 mg, 0.10 mmol). 1H
NMR (300 MHz, CDCl3): δH 8.54 (d, J = 5.0 Hz, 2H), 8.47 (d, J =
7.4 Hz, 1H), 8.41 (d, J = 8.4 Hz, 2H), 7.62–7.46 (m, 5H), 7.12 (t,
J = 6.4 Hz, 2H), 6.73 (d, J = 7.6 Hz, H), 5.22 (d, J = 17.0 Hz, 2H),
4.48–4.37 (m, 4H), 4.01–3.90 (m, 8H), 3.84 (s, 4H), 3.66 (t, J =
5.1 Hz, 2H) ppm. 13C{1H} NMR (151 MHz, CDCl3): δC 195.75,
195.36, 165.59, 165.12, 160.83, 150.51, 140.00, 134.96, 131.50,
129.88, 127.58, 125.25, 124.96, 124.50, 122.30, 120.33, 109.29,
104.33, 77.23, 77.02, 76.81, 70.45, 70.13, 68.39, 67.71, 67.41,
62.49, 43.29, 42.71 ppm. LRMS found m/z = 840.20 [M + H]+,
HRMS expected m/z = 840.2043 for [M + H]+, found m/z =
840.2029. FT-IR (solid, selected cm−1): 2031 (CuO), 1928
(CuO), 1683 (CvO), 1635 (CvO), 1058 (BF4
−). UV-vis. (MeCN)
λmax (ε/dm
3 mol−1 cm−1): 429 (8100), 279 (13 300), 262 (18 000)
nm.
Synthesis of fac-[Re(CO)3(L
6)]BF4. Prepared as for fac-[Re
(CO)3(L
5)]BF4 but using compound L
6 (62 mg, 1.0 mmol). 1H
NMR (300 MHz, CDCl3): δH 8.54 (d, J = 4.9 Hz, 2H), 8.50–8.34
(m, 3H), 7.62–7.46 (m, 5H), 7.11 (app. t, J = 5.7 Hz, 2H), 6.73
(d, J = 8.4 Hz, 1H), 5.23 (d, J = 16.6 Hz, 2H), 4.46 (s, 1H), 4.40
(t, J = 6.3 Hz, 3H), 4.03–3.91 (m, 5H), 3.85 (s, 4H), 3.72 (t, J =
6.1 Hz, 3H), 3.69–3.63 (m, 2H), 3.39 (s, 3H) ppm. 13C{1H} NMR
(151 MHz, CD3OD): δC 195.81, 194.75, 164.73, 164.19, 160.54,
151.54, 151.12, 139.90, 134.49, 130.83, 129.85, 127.58, 125.12,
124.34, 122.95, 122.07, 120.19, 108.16, 103.83, 70.22, 70.10,
69.35, 69.27, 68.63, 68.04, 67.77, 57.48, 42.96, 38.36 ppm.
LRMS found m/z = 854.21 [M]+, HRMS expected m/z = 854.2196
for [M]+, found m/z = 854.2190. FT-IR (solid, selected cm−1):
2029 (CuO), 1908 (CuO), 1684 (CvO), 1645 (CvO), 1057
(BF4
−). UV-vis. (MeCN) λmax (ε/dm
3 mol−1 cm−1): 430 (12 240),
281 (21 000), 261 (23 100) nm.
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